Large Molecule Bioanalysis done differently

To help you achieve more.

BioAgilytix has evolved the model for partnership in large molecule bioanalysis to benefit our customers and the patients they serve.

Services Delivered Scientist to Scientist

Our fully integrated GxP services are driven by your assay requirements and delivered by our veteran scientists – collaboratively, accurately, and on time.

biomarkers

Biomarkers

immunogenicity

Immunogenicity

pharmacokinetics

Pharmacokinetics (PK)

cell-based-assays

Cell-Based Assays

Solutions Enabled by World-Leading Expertise

Our team is comprised of recognized experts in effectively navigating complex and evolving opportunities for biotherapeutics innovation.

biosimilars

Biosimilars

gene-therapy

Gene Therapy

antibody-drug-conjugates

Antibody Drug Conjugates (ADCs)

immuno-oncology

Immuno-oncology

The Bioagilytix Perspective

Explore the BioAgilytix way of thinking. Visit our Resource Center to learn more about our scientists’ expertise through case studies, blogs, industry articles and other scientific resources.

resource center

Visit Resource Center

usa europe labs

Advanced facilities to support all phases of large molecule global studies.

    LinkedIn Company Updates

  • Today Agoview on linkedin

    BioAgilytix

    How a CRO approaches technology investment is an excellent way to evaluate its priorities and commitment to strategic innovation. In this blog, Afshin Safavi discusses why starting with study requirements is the best way to decide which bioanalytical platforms to acquire: https://lnkd.in/gvYKBuJ

  • Today Agoview on linkedin

    BioAgilytix

    BioAgilytix remains committed to diversity as our global growth accelerates. Thus far in 2018, we have brought on 69 new team members between our USA and European locations, and nearly half of these new hires come from minority backgrounds: https://lnkd.in/dZYMdzU

  • Today Agoview on linkedin

    BioAgilytix

    According to researchers at Brigham and Women's Hospital, checkpoint blockade immunotherapy provided significant improvements in overall survival for patients with melanoma brain metastases. The success of this therapy has the potential to overhaul the standard of care for patients with advanced melanoma. Read more via Genetic Engineering & Biotechnology News: https://lnkd.in/gjSeWxj